[ORGANIZATION]
Ideaya Biosciences
Featured in 2 tracked stories · first seen
Situations
Replimune Tudriqev FDA approval and subsequent legal action
5 clusters · 20 sources · last updated
Latest: Replimune faces lawsuits following TUDRIQEV approval
On 6 August 2026, the FDA granted accelerated approval to Replimune’s oncolytic herpes-virus therapy RP1, marketed as Tudriqev, for use with Bristol Myers Squibb’s Opdivo (nivolumab) in adults with unresectable or metast
Also covered in
-
IDEAYA Biosciences and Genentech partner on pancreatic cancer clinical trial
[BUSINESS] · 2 sources ·